The facility layout is strategically designed to accommodate the various stages of topical product production. With a commitment to excellence, HPL continuously seeks to enhance its capabilities, which includes conceptualizing a new facility for topical production, with plans for establishment by 2026. This expansion will further strengthen HPL’s position in the market by increasing production capacity and improving operational efficiencies.

The Topical Production Unit adheres to Good Manufacturing Practices (GMP) approved by the Directorate General of Drug Administration (DGDA).

The Topical Production Unit specializes in the manufacturing of creams, ointments, and medicated gels. This facility is equipped with modern production technologies, operated by a skilled workforce dedicated to maintaining the highest standards of quality. Each product undergoes rigorous quality checks to ensure compliance with safety and efficacy requirements.

HPL’s Quality Management System (QMS) for the Topical Production Unit aligns with local regulatory guidelines, incorporating essential practices to maintain product quality and safety. While specific upcoming GMP plans are not currently established, HPL remains committed to continuous improvement and adaptation to industry standards.

With a rich history of production since its inception in 2010, HPL’s Topical Production Unit stands as a pillar of reliability in the pharmaceutical industry, dedicated to delivering effective topical therapies that meet the diverse needs of patients. Through innovation and adherence to quality standards, HPL aims to expand its product offerings while continuing to ensure the highest level of patient care.